In the phase 3 study, Relatlimab (anti-LAG3, lymphocyte activation gene-3) in combination with Nivolumab (anti-PD-1) provided a greater progression-free survival (PFS) benefit than Nivolumab monotherapy in melanoma patients (2), leading to regulatory approval by USA FDA to treat unresectable or metastatic melanoma. The gene discussed is PDCD1; the disease is melanoma.